Georgalas Ilias, Paraskevopoulos Theodore, Papaconstaninou Dimitris, Brouzas Dimitiris, Koutsandrea Chryssanthi
Department of Ophthalmology, "G Gennimatas" Hospital of Athens, NHS, University of Athens, Athens, Greece.
Clin Ophthalmol. 2013;7:707-9. doi: 10.2147/OPTH.S38951. Epub 2013 Apr 10.
To report a case of a patient receiving tamoxifen with visual deterioration and describe the unusual optical coherence tomography (OCT) findings.
Observational case report.
A 55-year-old female patient was referred to our department complaining of gradual visual deterioration in both eyes. Medical history was unremarkable apart from breast cancer for which she had received tamoxifen for 10 years (mean dosage 20 mg/day). Best corrected visual acuity was 20/400 in her right eye and 20/40 in her left eye. Fundoscopy in both eyes was without any obvious signs of maculopathy. However, Fourier-domain OCT demonstrated bilateral extensive areas of disruption in inner retinal layers without any signs of crystalline retinopathy. Six months after the cessation of tamoxifen, the situation remains unchanged.
Patients receiving tamoxifen should be monitored with high-resolution OCT for fundoscopically invisible changes in the inner retinal layers, the progression of which may seriously affect the patient's vision and subsequently their quality of life.
报告一例接受他莫昔芬治疗后出现视力下降的患者,并描述其不寻常的光学相干断层扫描(OCT)结果。
观察性病例报告。
一名55岁女性患者因双眼视力逐渐下降转诊至我科。除乳腺癌外,病史无异常,她接受他莫昔芬治疗10年(平均剂量20毫克/天)。右眼最佳矫正视力为20/400,左眼为20/40。双眼眼底检查未发现任何明显的黄斑病变迹象。然而,傅里叶域OCT显示双侧视网膜内层广泛区域中断,无结晶性视网膜病变迹象。停用他莫昔芬6个月后,情况仍未改变。
接受他莫昔芬治疗的患者应使用高分辨率OCT监测视网膜内层在眼底镜下不可见的变化,其进展可能严重影响患者视力及随后的生活质量。